Dominika Krupnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dominika Krupnik has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Joanna Górak
COPERNICUS PL Sp. z o.o., St. Adalbert Hospital, Jana Pawła II Avenue 50, 80-462 Gdańsk, Poland
8 shared publications - Krzysztof Hober
Healthcare Center in Olesno, Olesno, Poland
8 shared publications - Mateusz Skowron
Primary Healthcare Center in Kęty, Kęty, Poland
8 shared publications - Monika Łapot
COPERNICUS PL Sp. z o.o., St. Adalbert Hospital, Jana Pawła II Avenue 50, 80-462 Gdańsk, Poland
8 shared publications - Patrycja Szwemińska
Friedrich Lange County Hospital in Nowe Miasto Lubawskie, Mickiewicza 10, 13-300 Nowe Miasto Lubawskie, Poland
8 shared publications - Wiktoria Bzdak
Medical University of Bialystok, Jana Kilińskiego 1, 15-089 Bialystok, Poland
8 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
LARGE LANGUAGE MODEL–BASED CHATBOTS IN MENTAL HEALTH SUPPORT: A NARRATIVE REVIEW OF OPPORTUNITIES, RISKS, AND ETHICAL CHALLENGES
Background: Mental disorders represent a major global public health challenge. Mental health care is affected by limited access to services, shortages of mental health professionals, stigma, and growing healthcare costs. In response to these challenges, artificial intelligence-based technologies, including chatbots and large language models, are increasingly being explored as tools to support mental health care. Aim: The aim of this narrative review was to examine the potential benefits, risks, and ethical challenges associated with the use of artificial intelligence chatbots and large language model-based systems in mental health care. Particular attention was given to their clinical relevance, public health implications, and responsible implementation. Methods: A narrative review of the literature was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Publications written in English and published between January 2013 and March 2026 were considered. Thematic synthesis focused on technological applications, clinical utility, system-level implications, risks, and ethical and regulatory challenges. Results: Current evidence suggests that AI-based chatbots may support psychoeducation, emotional support, self-management, symptom monitoring, cognitive behavioral therapy-based exercises, and access to low-intensity mental health support. These tools may be particularly useful in settings with limited access to specialists and for individuals facing barriers related to stigma, cost, or availability of services. However, their use is associated with important risks, including inaccurate or harmful responses, privacy concerns, algorithmic bias, limited transparency, unclear accountability, emotional dependence, and insufficient long-term clinical validation. Conclusion: AI chatbots and large language model-based systems should be considered adjunctive tools rather than replacements for mental health professionals. Their safe and ethical integration into mental health care requires clinical validation, human oversight, transparent governance, privacy protection, bias assessment, crisis protocols, and continuous monitoring.
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessLARGE LANGUAGE MODEL–BASED CHATBOTS IN MENTAL HEALTH SUPPORT: A NARRATIVE REVIEW OF OPPORTUNITIES, RISKS, AND ETHICAL CHALLENGES
Background: Mental disorders represent a major global public health challenge. Mental health care is affected by limited access to services, shortages of mental health professionals, stigma, and growing healthcare costs. In response to these challenges, artificial intelligence-based technologies, including chatbots and large language models, are increasingly being explored as tools to support mental health care. Aim: The aim of this narrative review was to examine the potential benefits, risks, and ethical challenges associated with the use of artificial intelligence chatbots and large language model-based systems in mental health care. Particular attention was given to their clinical relevance, public health implications, and responsible implementation. Methods: A narrative review of the literature was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Publications written in English and published between January 2013 and March 2026 were considered. Thematic synthesis focused on technological applications, clinical utility, system-level implications, risks, and ethical and regulatory challenges. Results: Current evidence suggests that AI-based chatbots may support psychoeducation, emotional support, self-management, symptom monitoring, cognitive behavioral therapy-based exercises, and access to low-intensity mental health support. These tools may be particularly useful in settings with limited access to specialists and for individuals facing barriers related to stigma, cost, or availability of services. However, their use is associated with important risks, including inaccurate or harmful responses, privacy concerns, algorithmic bias, limited transparency, unclear accountability, emotional dependence, and insufficient long-term clinical validation. Conclusion: AI chatbots and large language model-based systems should be considered adjunctive tools rather than replacements for mental health professionals. Their safe and ethical integration into mental health care requires clinical validation, human oversight, transparent governance, privacy protection, bias assessment, crisis protocols, and continuous monitoring.
- Open Access
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
DIABULIMIA IN YOUNG ADULTS WITH TYPE 1 DIABETES: THE POTENTIAL OF CONTINUOUS GLUCOSE MONITORING DATA FOR EARLY DETECTION OF DISORDERED EATING BEHAVIORS – A SYSTEMATIC REVIEW
Diabulimia is a disorder that occurs in people with type 1 diabetes, characterized by the deliberate reduction or omission of insulin doses in order to lose weight. This behavior is associated with worse glycemic control and an increased risk of acute and chronic complications of diabetes. The aim of this review article was to analyze the current evidence on diabulimia in young adults with type 1 diabetes and to assess the potential of data from Continuous Glucose Monitoring (CGM) systems in the early detection of eating disorders. The literature review was based on publications retrieved from the PubMed, ScienceDirect, Scopus, and Google Scholar databases. The analysis showed that individuals who intentionally omit insulin are more likely to have higher HbA1c levels, experience episodes of diabetic ketoacidosis, and exhibit abnormal glycemic patterns visible in CGM data. The available studies suggest that analysis of CGM parameters may support earlier identification of patients at risk for diabulimia; however, further research is needed to confirm their diagnostic value.
- 30 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessDIABULIMIA IN YOUNG ADULTS WITH TYPE 1 DIABETES: THE POTENTIAL OF CONTINUOUS GLUCOSE MONITORING DATA FOR EARLY DETECTION OF DISORDERED EATING BEHAVIORS – A SYSTEMATIC REVIEW
Diabulimia is a disorder that occurs in people with type 1 diabetes, characterized by the deliberate reduction or omission of insulin doses in order to lose weight. This behavior is associated with worse glycemic control and an increased risk of acute and chronic complications of diabetes. The aim of this review article was to analyze the current evidence on diabulimia in young adults with type 1 diabetes and to assess the potential of data from Continuous Glucose Monitoring (CGM) systems in the early detection of eating disorders. The literature review was based on publications retrieved from the PubMed, ScienceDirect, Scopus, and Google Scholar databases. The analysis showed that individuals who intentionally omit insulin are more likely to have higher HbA1c levels, experience episodes of diabetic ketoacidosis, and exhibit abnormal glycemic patterns visible in CGM data. The available studies suggest that analysis of CGM parameters may support earlier identification of patients at risk for diabulimia; however, further research is needed to confirm their diagnostic value.
- Open Access
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
SELECTED PLANT-DERIVED POLYPHENOLS IN THE PREVENTION OF CIVILIZATION DISEASES: IMPLICATIONS FOR HEALTH AND NUTRITION EDUCATION
Civilization diseases — including obesity, type 2 diabetes, cardiovascular disease, osteoporosis, and selected cancers — are non-communicable conditions closely tied to modern lifestyle patterns, and they account for a substantial share of premature mortality worldwide. A growing body of evidence indicates that dietary polyphenols, a broad group of plant secondary metabolites, may play a meaningful role in the prevention of these conditions. This article presents a narrative review of the literature on the classification, dietary sources, and physiological activity of the main polyphenol subgroups — flavonoids, phenolic acids, stilbenes, and lignans — and synthesizes evidence on their preventive potential in diabetes, cardiovascular disease, osteoporosis, and cancer. Amaranth is discussed as an illustrative example of a polyphenol-rich functional food. The review further considers the practical implications of this evidence for nutrition and health education, arguing that translating polyphenol research into accessible dietary guidance is an important, and currently underused, tool of non-communicable disease prevention. The findings support the inclusion of plant-based, polyphenol-rich dietary patterns in public health and patient education programs, while noting that most available evidence remains observational or preclinical and that further controlled clinical research is warranted.
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessSELECTED PLANT-DERIVED POLYPHENOLS IN THE PREVENTION OF CIVILIZATION DISEASES: IMPLICATIONS FOR HEALTH AND NUTRITION EDUCATION
Civilization diseases — including obesity, type 2 diabetes, cardiovascular disease, osteoporosis, and selected cancers — are non-communicable conditions closely tied to modern lifestyle patterns, and they account for a substantial share of premature mortality worldwide. A growing body of evidence indicates that dietary polyphenols, a broad group of plant secondary metabolites, may play a meaningful role in the prevention of these conditions. This article presents a narrative review of the literature on the classification, dietary sources, and physiological activity of the main polyphenol subgroups — flavonoids, phenolic acids, stilbenes, and lignans — and synthesizes evidence on their preventive potential in diabetes, cardiovascular disease, osteoporosis, and cancer. Amaranth is discussed as an illustrative example of a polyphenol-rich functional food. The review further considers the practical implications of this evidence for nutrition and health education, arguing that translating polyphenol research into accessible dietary guidance is an important, and currently underused, tool of non-communicable disease prevention. The findings support the inclusion of plant-based, polyphenol-rich dietary patterns in public health and patient education programs, while noting that most available evidence remains observational or preclinical and that further controlled clinical research is warranted.
- Open Access
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
POTENTIAL USE OF GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF CHRONIC PAIN SYNDROMES: ANTI-INFLAMMATORY AND NEUROPROTECTIVE PERSPECTIVES
Chronic pain syndromes remain a major clinical and public health challenge because of their multifactorial pathophysiology, frequent refractoriness to standard treatment, and marked effects on quality of life, disability, sleep, psychological well-being, and work capacity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have recently attracted growing interest beyond metabolic medicine because their biological actions appear to extend to anti-inflammatory, antioxidative, neuroprotective, and cytoprotective pathways. These pleiotropic properties are potentially relevant to chronic pain, which is increasingly understood as a condition sustained not only by nociceptive input but also by neuroinflammation, glial activation, oxidative stress, maladaptive neuronal plasticity, mitochondrial dysfunction, and metabolic dysregulation. This narrative review examines the current biological and translational rationale for GLP-1RAs in chronic pain syndromes, with emphasis on neuropathic pain, diabetic peripheral neuropathy, migraine-related central sensitization, fibromyalgia-related mechanisms, osteoarthritis-associated pain, inflammatory musculoskeletal pain, and visceral pain. Available evidence suggests that GLP-1 receptor activation may modulate several processes implicated in pain chronification, including pro-inflammatory cytokine signaling, microglial activation, oxidative stress, mitochondrial dysfunction, and impaired neuronal resilience. Experimental studies also indicate possible involvement of IL-10-mediated anti-inflammatory signaling, AMPK/NF-kappaB pathway modulation, and broader neuroimmune regulation. However, the current evidence base remains heterogeneous and is still dominated by preclinical studies, mechanistic reviews, and early observational data. Human evidence in non-diabetic chronic pain populations remains limited, and in many settings it is difficult to separate direct analgesic effects from indirect benefits related to weight loss, improved glycemic control, reduced systemic inflammation, or improved function. At present, GLP-1RAs should therefore be regarded as biologically plausible and clinically promising, but still investigational, candidates in chronic pain management rather than established analgesic therapies. Further translational work and adequately powered prospective clinical studies are required to clarify efficacy, safety, mechanism-specific effects, and phenotype-specific patient selection.
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessPOTENTIAL USE OF GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF CHRONIC PAIN SYNDROMES: ANTI-INFLAMMATORY AND NEUROPROTECTIVE PERSPECTIVES
Chronic pain syndromes remain a major clinical and public health challenge because of their multifactorial pathophysiology, frequent refractoriness to standard treatment, and marked effects on quality of life, disability, sleep, psychological well-being, and work capacity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have recently attracted growing interest beyond metabolic medicine because their biological actions appear to extend to anti-inflammatory, antioxidative, neuroprotective, and cytoprotective pathways. These pleiotropic properties are potentially relevant to chronic pain, which is increasingly understood as a condition sustained not only by nociceptive input but also by neuroinflammation, glial activation, oxidative stress, maladaptive neuronal plasticity, mitochondrial dysfunction, and metabolic dysregulation. This narrative review examines the current biological and translational rationale for GLP-1RAs in chronic pain syndromes, with emphasis on neuropathic pain, diabetic peripheral neuropathy, migraine-related central sensitization, fibromyalgia-related mechanisms, osteoarthritis-associated pain, inflammatory musculoskeletal pain, and visceral pain. Available evidence suggests that GLP-1 receptor activation may modulate several processes implicated in pain chronification, including pro-inflammatory cytokine signaling, microglial activation, oxidative stress, mitochondrial dysfunction, and impaired neuronal resilience. Experimental studies also indicate possible involvement of IL-10-mediated anti-inflammatory signaling, AMPK/NF-kappaB pathway modulation, and broader neuroimmune regulation. However, the current evidence base remains heterogeneous and is still dominated by preclinical studies, mechanistic reviews, and early observational data. Human evidence in non-diabetic chronic pain populations remains limited, and in many settings it is difficult to separate direct analgesic effects from indirect benefits related to weight loss, improved glycemic control, reduced systemic inflammation, or improved function. At present, GLP-1RAs should therefore be regarded as biologically plausible and clinically promising, but still investigational, candidates in chronic pain management rather than established analgesic therapies. Further translational work and adequately powered prospective clinical studies are required to clarify efficacy, safety, mechanism-specific effects, and phenotype-specific patient selection.
- Open Access
- 27 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE IMPACT OF ARTIFICIAL INTELLIGENCE ON THE DIAGNOSIS AND TREATMENT OF MENTAL DISORDERS: A REVIEW OF CURRENT RESEARCH
Mental disorders constitute a major global public health challenge, affecting more than one billion people worldwide and contributing substantially to disability, reduced quality of life, and increased healthcare costs. In recent years, artificial intelligence (AI) has emerged as a promising tool for improving the diagnosis, monitoring, and treatment of psychiatric disorders. This review aims to examine current research on the application of AI in mental health care, with particular emphasis on its role in diagnostic assessment, treatment planning, patient monitoring, and digital therapeutic interventions. A narrative review of recent literature published between 2020 and 2026 was conducted using major scientific databases and peer-reviewed publications. The reviewed studies focused on machine learning algorithms, natural language processing, predictive analytics, AI-assisted clinical decisionmaking, and conversational agents used in psychiatric settings. The findings indicate that AI technologies demonstrate significant potential in enhancing diagnostic accuracy, identifying early signs of mental disorders, predicting treatment outcomes, and supporting personalized care. Machine learning models have shown promising results in the detection of depression, anxiety disorders, schizophrenia, and bipolar disorder through the analysis of speech, behavioral, neuroimaging, and electronic health record data. Furthermore, AI-powered chatbots and digital mental health platforms may improve access to psychological support and facilitate continuous patient monitoring. Despite these advantages, important challenges remain, including concerns regarding data privacy, algorithmic bias, transparency, ethical governance, and clinical validation. The successful integration of AI into psychiatric practice requires robust regulatory frameworks, interdisciplinary collaboration, and continued research to ensure safe, equitable, and effective implementation in mental health care.
- 27 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE IMPACT OF ARTIFICIAL INTELLIGENCE ON THE DIAGNOSIS AND TREATMENT OF MENTAL DISORDERS: A REVIEW OF CURRENT RESEARCH
Mental disorders constitute a major global public health challenge, affecting more than one billion people worldwide and contributing substantially to disability, reduced quality of life, and increased healthcare costs. In recent years, artificial intelligence (AI) has emerged as a promising tool for improving the diagnosis, monitoring, and treatment of psychiatric disorders. This review aims to examine current research on the application of AI in mental health care, with particular emphasis on its role in diagnostic assessment, treatment planning, patient monitoring, and digital therapeutic interventions. A narrative review of recent literature published between 2020 and 2026 was conducted using major scientific databases and peer-reviewed publications. The reviewed studies focused on machine learning algorithms, natural language processing, predictive analytics, AI-assisted clinical decisionmaking, and conversational agents used in psychiatric settings. The findings indicate that AI technologies demonstrate significant potential in enhancing diagnostic accuracy, identifying early signs of mental disorders, predicting treatment outcomes, and supporting personalized care. Machine learning models have shown promising results in the detection of depression, anxiety disorders, schizophrenia, and bipolar disorder through the analysis of speech, behavioral, neuroimaging, and electronic health record data. Furthermore, AI-powered chatbots and digital mental health platforms may improve access to psychological support and facilitate continuous patient monitoring. Despite these advantages, important challenges remain, including concerns regarding data privacy, algorithmic bias, transparency, ethical governance, and clinical validation. The successful integration of AI into psychiatric practice requires robust regulatory frameworks, interdisciplinary collaboration, and continued research to ensure safe, equitable, and effective implementation in mental health care.
- Open Access
- 27 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
FLEXOR TENOSYNOVITIS OF THE WRIST: A COMPREHENSIVE REVIEW OF CURRENT KNOWLEDGE
Introduction and purpose. Flexor tenosynovitis of the wrist is inflammation of the volar (palmar) flexor tendon sheaths, an under-recognized but clinically important cause of volar wrist pain, swelling, and median-nerve symptoms. It spans mechanical, calcific, inflammatory, and infective forms that mimic one another and delay correct treatment. This review consolidates current knowledge on its anatomy, etiology, diagnosis, and management. Materials and methods. This review synthesized 55 articles, spanning 1940 to 2026, identified through an extensive search of PubMed and limited to English-language publications; no date restriction was applied, so that landmark anatomical descriptions could be retained alongside contemporary practice. Data were synthesized descriptively, organized by pathophysiology, clinical presentation, diagnosis, and management. Description of the state of knowledge. The condition comprises mechanical (notably flexor carpi radialis), calcific, inflammatory (rheumatoid), and infective (pyogenic, tuberculous, nontuberculous mycobacterial, and fungal) forms that overlap clinically and may compress the median nerve, causing secondary carpal tunnel syndrome. Diagnosis combines clinical examination with radiographs, ultrasound, and magnetic resonance imaging, supplemented by histopathology or culture when the cause is unclear. Management is form-specific, ranging from immobilization and anti-inflammatory drugs for self-limiting calcific disease, through corticosteroid injection, to tenosynovectomy with carpal tunnel release and urgent debridement for pyogenic infection, in which delay worsens outcomes. Conclusions. Flexor tenosynovitis of the wrist is uncommon, etiologically diverse, and frequently misdiagnosed; early differentiation of its forms is the key to correct treatment. The evidence base rests largely on case reports and retrospective series rather than controlled trials.
- 27 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessFLEXOR TENOSYNOVITIS OF THE WRIST: A COMPREHENSIVE REVIEW OF CURRENT KNOWLEDGE
Introduction and purpose. Flexor tenosynovitis of the wrist is inflammation of the volar (palmar) flexor tendon sheaths, an under-recognized but clinically important cause of volar wrist pain, swelling, and median-nerve symptoms. It spans mechanical, calcific, inflammatory, and infective forms that mimic one another and delay correct treatment. This review consolidates current knowledge on its anatomy, etiology, diagnosis, and management. Materials and methods. This review synthesized 55 articles, spanning 1940 to 2026, identified through an extensive search of PubMed and limited to English-language publications; no date restriction was applied, so that landmark anatomical descriptions could be retained alongside contemporary practice. Data were synthesized descriptively, organized by pathophysiology, clinical presentation, diagnosis, and management. Description of the state of knowledge. The condition comprises mechanical (notably flexor carpi radialis), calcific, inflammatory (rheumatoid), and infective (pyogenic, tuberculous, nontuberculous mycobacterial, and fungal) forms that overlap clinically and may compress the median nerve, causing secondary carpal tunnel syndrome. Diagnosis combines clinical examination with radiographs, ultrasound, and magnetic resonance imaging, supplemented by histopathology or culture when the cause is unclear. Management is form-specific, ranging from immobilization and anti-inflammatory drugs for self-limiting calcific disease, through corticosteroid injection, to tenosynovectomy with carpal tunnel release and urgent debridement for pyogenic infection, in which delay worsens outcomes. Conclusions. Flexor tenosynovitis of the wrist is uncommon, etiologically diverse, and frequently misdiagnosed; early differentiation of its forms is the key to correct treatment. The evidence base rests largely on case reports and retrospective series rather than controlled trials.
- Open Access
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
CHILDHOOD OBESITY AND GLP-1 RECEPTOR AGONISTS: CURRENT EVIDENCE, CHALLENGES AND FUTURE PERSPECTIVES – A NARRATIVE REVIEW
Introduction: Childhood obesity has become one of the most significant global public health challenges of the twenty-first century. The prevalence of obesity among children and adolescents continues to increase worldwide, contributing to the growing burden of metabolic, cardiovascular, endocrine and psychological disorders. Traditional interventions based on lifestyle modification often demonstrate limited long-term effectiveness, highlighting the need for additional therapeutic strategies. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising pharmacological option for pediatric obesity management. Purpose of the Study: The aim of this review is to provide a comprehensive overview of the current evidence regarding the use of GLP-1 receptor agonists in children and adolescents with obesity, with particular emphasis on their mechanisms of action, clinical efficacy, safety profile, psychological impact and future therapeutic perspectives. Materials and Methods: The literature review was based on publications published between 2007 and 2025. PubMed, Scopus and Google Scholar databases were searched using keywords including childhood obesity, pediatric obesity, adolescent obesity, GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide, pharmacological treatment and weight management. Priority was given to randomized controlled trials, systematic reviews, meta-analyses and international clinical guidelines published in English. Description of the State of Knowledge: Recent clinical trials have demonstrated significant efficacy of GLP-1 receptor agonists in reducing body weight and body mass index in pediatric patients with obesity. Liraglutide and semaglutide have shown clinically meaningful improvements in weight reduction, metabolic parameters and quality of life. Among currently available GLP-1 receptor agonists, semaglutide demonstrated the greatest efficacy for BMI and weight reduction in a recent network meta-analysis of pediatric obesity treatments. Although gastrointestinal adverse effects remain the most commonly reported complications, overall treatment tolerability appears favorable. Ongoing studies are evaluating long-term safety, treatment durability and the role of next-generation incretin-based therapies. Conclusion: GLP-1 receptor agonists represent a promising advancement in the management of childhood obesity. Their ability to achieve significant weight reduction and improve obesity-related comorbidities may substantially decrease the lifetime risk of cardiovascular disease, chronic kidney disease,and premature mortality.
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessCHILDHOOD OBESITY AND GLP-1 RECEPTOR AGONISTS: CURRENT EVIDENCE, CHALLENGES AND FUTURE PERSPECTIVES – A NARRATIVE REVIEW
Introduction: Childhood obesity has become one of the most significant global public health challenges of the twenty-first century. The prevalence of obesity among children and adolescents continues to increase worldwide, contributing to the growing burden of metabolic, cardiovascular, endocrine and psychological disorders. Traditional interventions based on lifestyle modification often demonstrate limited long-term effectiveness, highlighting the need for additional therapeutic strategies. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising pharmacological option for pediatric obesity management. Purpose of the Study: The aim of this review is to provide a comprehensive overview of the current evidence regarding the use of GLP-1 receptor agonists in children and adolescents with obesity, with particular emphasis on their mechanisms of action, clinical efficacy, safety profile, psychological impact and future therapeutic perspectives. Materials and Methods: The literature review was based on publications published between 2007 and 2025. PubMed, Scopus and Google Scholar databases were searched using keywords including childhood obesity, pediatric obesity, adolescent obesity, GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide, pharmacological treatment and weight management. Priority was given to randomized controlled trials, systematic reviews, meta-analyses and international clinical guidelines published in English. Description of the State of Knowledge: Recent clinical trials have demonstrated significant efficacy of GLP-1 receptor agonists in reducing body weight and body mass index in pediatric patients with obesity. Liraglutide and semaglutide have shown clinically meaningful improvements in weight reduction, metabolic parameters and quality of life. Among currently available GLP-1 receptor agonists, semaglutide demonstrated the greatest efficacy for BMI and weight reduction in a recent network meta-analysis of pediatric obesity treatments. Although gastrointestinal adverse effects remain the most commonly reported complications, overall treatment tolerability appears favorable. Ongoing studies are evaluating long-term safety, treatment durability and the role of next-generation incretin-based therapies. Conclusion: GLP-1 receptor agonists represent a promising advancement in the management of childhood obesity. Their ability to achieve significant weight reduction and improve obesity-related comorbidities may substantially decrease the lifetime risk of cardiovascular disease, chronic kidney disease,and premature mortality.
- Open Access
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
PROBLEMATIC SMARTPHONE USE AND ITS IMPACT ON MENTAL HEALTH, PHYSICAL WELL-BEING, AND SOCIAL FUNCTIONING: A NARRATIVE REVIEW
Introduction: Problematic smartphone use (PSU), often referred to as smartphone addiction, has emerged as a growing public health and social concern in the digital era. The widespread availability of smartphones has transformed communication, education, and access to information; however, excessive and uncontrolled use has been associated with numerous adverse psychological, physical, social, and academic outcomes. The increasing prevalence of PSU, particularly among adolescents and young adults, has attracted significant attention from researchers, healthcare professionals, and policymakers. Purpose of the Study: The aim of this narrative review is to provide a comprehensive overview of problematic smartphone use, including its epidemiology, risk factors, neurobiological mechanisms, assessment methods, mental and physical health consequences, social and educational impacts, and current prevention and intervention strategies. Description of the State of Knowledge: Problematic smartphone use is characterized by excessive, compulsive, and difficult-to-control engagement with smartphones, often resulting in impaired daily functioning. Epidemiological studies indicate considerable variation in prevalence rates across populations and regions, with adolescents and young adults representing the most vulnerable groups. Multiple risk factors have been identified, including intensive social media use, gaming, fear of missing out (FOMO), psychological distress, loneliness, poor self-regulation, and excessive screen exposure. Current evidence suggests significant associations between PSU and depression, anxiety, stress, sleep disturbances, reduced quality of life, impaired academic achievement, and social difficulties. Physical health consequences include musculoskeletal complaints, headaches, visual fatigue, sedentary behavior, and sleep-related problems. Recent studies have also highlighted the importance of digital well-being tools, educational programs, family-based approaches, and cognitive-behavioral interventions in promoting healthier smartphone use habits. Conclusion: Problematic smartphone use represents a complex and multifactorial phenomenon with important implications for mental health, physical well-being, social functioning, and academic performance. Greater awareness, early preventive measures, and evidence-based intervention strategies may help reduce its negative consequences. Future research should focus on longitudinal studies, standardized assessment methods, and the development of effective prevention and treatment approaches.
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessPROBLEMATIC SMARTPHONE USE AND ITS IMPACT ON MENTAL HEALTH, PHYSICAL WELL-BEING, AND SOCIAL FUNCTIONING: A NARRATIVE REVIEW
Introduction: Problematic smartphone use (PSU), often referred to as smartphone addiction, has emerged as a growing public health and social concern in the digital era. The widespread availability of smartphones has transformed communication, education, and access to information; however, excessive and uncontrolled use has been associated with numerous adverse psychological, physical, social, and academic outcomes. The increasing prevalence of PSU, particularly among adolescents and young adults, has attracted significant attention from researchers, healthcare professionals, and policymakers. Purpose of the Study: The aim of this narrative review is to provide a comprehensive overview of problematic smartphone use, including its epidemiology, risk factors, neurobiological mechanisms, assessment methods, mental and physical health consequences, social and educational impacts, and current prevention and intervention strategies. Description of the State of Knowledge: Problematic smartphone use is characterized by excessive, compulsive, and difficult-to-control engagement with smartphones, often resulting in impaired daily functioning. Epidemiological studies indicate considerable variation in prevalence rates across populations and regions, with adolescents and young adults representing the most vulnerable groups. Multiple risk factors have been identified, including intensive social media use, gaming, fear of missing out (FOMO), psychological distress, loneliness, poor self-regulation, and excessive screen exposure. Current evidence suggests significant associations between PSU and depression, anxiety, stress, sleep disturbances, reduced quality of life, impaired academic achievement, and social difficulties. Physical health consequences include musculoskeletal complaints, headaches, visual fatigue, sedentary behavior, and sleep-related problems. Recent studies have also highlighted the importance of digital well-being tools, educational programs, family-based approaches, and cognitive-behavioral interventions in promoting healthier smartphone use habits. Conclusion: Problematic smartphone use represents a complex and multifactorial phenomenon with important implications for mental health, physical well-being, social functioning, and academic performance. Greater awareness, early preventive measures, and evidence-based intervention strategies may help reduce its negative consequences. Future research should focus on longitudinal studies, standardized assessment methods, and the development of effective prevention and treatment approaches.
- Open Access
- 16 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1557
Urine Metanephrine Concentration Can Early and Accurately Predict Etiology of Acute Respiratory Failure in Critically Ill Patients with Subarachnoid Hemorrhage: A Prospective Single-Center Pilot Study
Background: Subarachnoid hemorrhage (SAH) can cause remote organ failure through complex systemic reactions. Acute respiratory failure (ARF) in the course of SAH may have a diverse etiology, including cardiogenic origin. The aim of the study was to evaluate the utility of urine metanephrine measurement in identifying the ARF phenotype in patients with SAH. Methods: A prospective single-center study was conducted between January 2022 and February 2023. The study included consecutive adult patients admitted to the Intensive Care Unit (ICU) within 24 h of SAH diagnosis and requiring mechanical ventilation due to ARF within the first 48 h of stay. Demographic and clinical data were collected. Metanephrine (MET) was determined in 24-h urine collection. The inflammatory profile was assessed by measuring serum levels of interleukin-6 (IL-6), CRP, and PCT. Cardiogenic ARF phenotype was diagnosed when concomitant elevation of hsTpI, CK-MB, and NT-proBNP was observed upon admission. Results: The study group consisted of 18 patients. The cardiogenic etiology group (n = 4) was characterized by higher MET concentrations (249 vs. 63.5 ng/mL; p = 0.007) and a lower oxygenation index (190 vs. 296 mmHg; p < 0.05) on admission. In the non-cardiogenic etiology group (n = 14), higher levels of IL-6 were found (34 vs. 8.3 pg/mL; p = 0.013). MET significantly correlated with the oxygenation index (R = −1.0; p < 0.001) on day 1 and with lactate levels on days 2 and 3 of stay (R = 1.0; p < 0.001). Baseline MET concentration accurately predicted the ARF phenotype (AUC 0.93; 95% CI 0.786–1.000, p = 0.008). Conclusions: Urine metanephrine levels show potential in differentiating the etiology of ARF and correlate with severity markers in critically ill SAH patients at an early stage. These preliminary results highlight the importance of a targeted approach to ARF diagnostics after SAH, which could support appropriate therapeutic decisions, although further validation in larger cohorts is required.
- 16 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1557
Open AccessUrine Metanephrine Concentration Can Early and Accurately Predict Etiology of Acute Respiratory Failure in Critically Ill Patients with Subarachnoid Hemorrhage: A Prospective Single-Center Pilot Study
Background: Subarachnoid hemorrhage (SAH) can cause remote organ failure through complex systemic reactions. Acute respiratory failure (ARF) in the course of SAH may have a diverse etiology, including cardiogenic origin. The aim of the study was to evaluate the utility of urine metanephrine measurement in identifying the ARF phenotype in patients with SAH. Methods: A prospective single-center study was conducted between January 2022 and February 2023. The study included consecutive adult patients admitted to the Intensive Care Unit (ICU) within 24 h of SAH diagnosis and requiring mechanical ventilation due to ARF within the first 48 h of stay. Demographic and clinical data were collected. Metanephrine (MET) was determined in 24-h urine collection. The inflammatory profile was assessed by measuring serum levels of interleukin-6 (IL-6), CRP, and PCT. Cardiogenic ARF phenotype was diagnosed when concomitant elevation of hsTpI, CK-MB, and NT-proBNP was observed upon admission. Results: The study group consisted of 18 patients. The cardiogenic etiology group (n = 4) was characterized by higher MET concentrations (249 vs. 63.5 ng/mL; p = 0.007) and a lower oxygenation index (190 vs. 296 mmHg; p < 0.05) on admission. In the non-cardiogenic etiology group (n = 14), higher levels of IL-6 were found (34 vs. 8.3 pg/mL; p = 0.013). MET significantly correlated with the oxygenation index (R = −1.0; p < 0.001) on day 1 and with lactate levels on days 2 and 3 of stay (R = 1.0; p < 0.001). Baseline MET concentration accurately predicted the ARF phenotype (AUC 0.93; 95% CI 0.786–1.000, p = 0.008). Conclusions: Urine metanephrine levels show potential in differentiating the etiology of ARF and correlate with severity markers in critically ill SAH patients at an early stage. These preliminary results highlight the importance of a targeted approach to ARF diagnostics after SAH, which could support appropriate therapeutic decisions, although further validation in larger cohorts is required.
- 2 July 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (5) , 64-71
Comprehensive care of the patient with Refeeding Syndrome
Introduction: Refeeding syndrome (RS) is a serious complication of nutritional therapy in critically ill patients, to which patients on surgical wards are particularly vulnerable. It is a potentially life-threatening, complex metabolic disorder that occurs in response to the implementation of overly aggressive, inadequate adaptive patient nutritional therapy, often exacerbated by malnutrition. Moreover, if an appropriate diagnostic and therapeutic process is not undertaken, RS itself becomes the cause of subsequent systemic complications such as respiratory failure, neurological disorders, circulatory failure or seizures. Identified risk factors for RS are mostly modifiable.Aim: The article reviews the literature on the current knowledge and recommendations regarding RS and provides practical recommendations to assist surgeons in effectively diagnosing and managing the syndrome during the perioperative period.Methods: A database query was conducted to identify the most recent information related to the topic of this study.Results: Treatment of RS in critically ill patients undergoing surgery is challenging due to overlapping symptoms of the underlying disease and coexisting severe metabolic disorders. Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient's metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment.Conclusions: It is necessary to regularly follow the recommendations of scientific societies, which will take into account the specificity of the treatment of patients in the perioperative period with Refeeding Syndrome in the context of coexisting diseases to improve the quality and safety of care of these patients.
- 2 July 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (5) , 64-71
Comprehensive care of the patient with Refeeding Syndrome
Introduction: Refeeding syndrome (RS) is a serious complication of nutritional therapy in critically ill patients, to which patients on surgical wards are particularly vulnerable. It is a potentially life-threatening, complex metabolic disorder that occurs in response to the implementation of overly aggressive, inadequate adaptive patient nutritional therapy, often exacerbated by malnutrition. Moreover, if an appropriate diagnostic and therapeutic process is not undertaken, RS itself becomes the cause of subsequent systemic complications such as respiratory failure, neurological disorders, circulatory failure or seizures. Identified risk factors for RS are mostly modifiable.Aim: The article reviews the literature on the current knowledge and recommendations regarding RS and provides practical recommendations to assist surgeons in effectively diagnosing and managing the syndrome during the perioperative period.Methods: A database query was conducted to identify the most recent information related to the topic of this study.Results: Treatment of RS in critically ill patients undergoing surgery is challenging due to overlapping symptoms of the underlying disease and coexisting severe metabolic disorders. Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient's metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment.Conclusions: It is necessary to regularly follow the recommendations of scientific societies, which will take into account the specificity of the treatment of patients in the perioperative period with Refeeding Syndrome in the context of coexisting diseases to improve the quality and safety of care of these patients.